Revolutionary Breakthrough: Unleashing the Power of B Cells and Plasma Cells for Effective Hidradenitis Suppurativa Treatment

B cell • Skin cancer • Hidradenitis suppurativa • Medicine 

Exciting news for patients suffering from hidradenitis suppurative (HS)! A recent study has revealed that treatment with fostamatinib, which focuses on targeting B cells and plasma cells, holds great potential in managing this debilitating disease.

Researchers led by Rebecca Jepsen from Sydney conducted a phase 2 proof-of-concept study involving 20 patients aged 18 and older with HS. The study aimed to assess the safety, tolerability, and efficacy of fostamatinib. The results were truly remarkable.

Patients received oral fostamatinib twice daily, starting with 100 mg for 4 weeks, followed by an escalation to 150 mg for the next 7 weeks. Notably, all patients completed the 12-week treatment period, with no major adverse effects reported.

The findings demonstrated significant improvements in the patient’s condition. Within the first week of treatment, a remarkable reduction in nodules and abscesses was observed. By week 4, an impressive 17 subjects achieved a 50% or greater improvement in the HS Clinical Response Score (HiSCR).

As treatment progressed, these positive outcomes continued to improve, with 85% of patients achieving HiSCR 50 at week 12, while 70% achieved HiSCR 75, and 25% achieved HiSCR 90.

Importantly, the study shed light on the role of B cells and plasma cells in the pathogenesis of HS. Fostamatinib, a spleen tyrosine kinase (SYK) antagonist, effectively targeted these cells, inhibiting the production of immunoglobulins by plasma cells and impeding the migration and activation of B cells.

The trial’s safety profile was encouraging, with mild adverse events reported, including nausea, hypertension, transaminitis, and diarrhea. Notably, hypertension in two patients was resolved by reducing the fostamatinib dose.

The remarkable clinical response within the initial weeks of treatment suggests that SYK may indeed serve as a promising therapeutic target for HS. The authors believe that combining SYK antagonism with other therapeutic agents could enhance treatment outcomes and provide further benefits for patients in the future.

This groundbreaking study offers hope to individuals living with HS, showcasing the potential of targeted therapies to effectively manage this challenging condition. As research continues in this exciting field, it brings us one step closer to improved treatment strategies and a better quality of life for HS patients.